Funding for this research was provided by:
Bio & Medical Technology Development Program of the National Research Foundation (2017M3A9B3061838, 2019R1A2C2005453)
Received: 25 September 2021
Accepted: 18 November 2021
First Online: 18 December 2021
: This study was approved and supervised by Ethical committee of Kangwon National University Hospital and Hallym University Medical Center. Written informed consent was provided by all participants.
: Not applicable.
: The NP-011 and the use of NP-011 for treating liver and lung fibrosis is protected by published and unpublished patents (KOR/10-1947902, PCT/ KR2017/005150, EU/17870624.8, JP/2018-524465, US/15/994.323, CN/ 201780004259.5, KOR/10-2018-0128625, and PCT/KR2018/012801), and these intellectual property rights are belonging to NEXEL. Co., Ltd.